Abstract
Current evidence suggests that concurrent RT/CHT is the standard of treatment in patients with locally advanced, inoperable NSCLC. This treatment approach, however, bears risk of increased toxicity and, therefore, must be carefully balanced regarding the choice of patients suitable for such an intervention. Newer RT technologies, third-generation CHT drugs, and widely used radioprotectors represent the current framework for numerous clinical studies that ultimately will help optimize the treatment of this disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 91-100 |
| Number of pages | 10 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2004 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
Fingerprint
Dive into the research topics of 'Concurrent radiochemotherapy in the treatment of locally advanced non-small cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver